Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237847 | 1.00 | SLC6A4 (0.38) | SLC6A4DRD4DRD2HTR7NPC1 | |
| SCHEMBL2237843 | 1.00 | SLC6A4 (0.38) | SLC6A4DRD4DRD2HTR7NPC1 | |
| SCHEMBL2237838 | 1.00 | SLC6A4 (0.38) | SLC6A4DRD4DRD2HTR7NPC1 | |
| SCHEMBL2237851 | 1.00 | SLC6A4 (0.38) | SLC6A4DRD4DRD2HTR7NPC1 | |
| SCHEMBL2235505 | 0.87 | GAA (0.31) | — | |
| SCHEMBL2238377 | 0.87 | SLC6A4 (0.39) | SLC6A4DRD4DRD2SIGMAR1 | |
| SCHEMBL2237091 | 0.87 | ESR1 (0.32) | NPC1RAB9A | |
| SCHEMBL2237082 | 0.87 | ESR1 (0.32) | NPC1RAB9A | |
| SCHEMBL2238374 | 0.87 | SLC6A4 (0.39) | SLC6A4DRD4DRD2SIGMAR1 | |
| SCHEMBL2237087 | 0.87 | ESR1 (0.32) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536687-A2 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120302756-A1 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| WO-2011103263-A2 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302756-A1 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | DHPS, ALDH18A1, QDPR | SLC6A4 1289/4885DRD4 15/4885DRD2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.